Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Non-Current Deferred Tax Liability (2009 - 2025)

Grifols' (GIFLF) quarterly Non-Current Deferred Tax Liability came in at $1.0 billion in Q4 2025, down 7.32% on a YoY basis from $1.1 billion in Q4 2024, and down 7.32% quarter-over-quarter from $1.1 billion in Q4 2024.

Analysis

Grifols (GIFLF) Non-Current Deferred Tax Liability (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Non-Current Deferred Tax Liability for 17 consecutive years, with $1.0 billion the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 7.32% year-over-year to $1.0 billion; the trailing twelve-month figure through Dec 2025 stood at $1.0 billion (down 7.32% YoY), and the FY2025 full-year result was $972.8 million, down 10.05% from the prior year.
  • Non-Current Deferred Tax Liability slipped to $1.0 billion in Q4 2025 per GIFLF's latest filing, from $1.1 billion in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $1.1 billion in Q4 2024 and bottomed at $725.3 million in Q4 2021.
  • Historically, Non-Current Deferred Tax Liability has averaged $985.7 million across 5 years, with a median of $1.1 billion in 2022.
  • The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability jumped 45.57% in 2022, then slipped 7.32% in 2025.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $725.3 million in 2021, then jumped by 45.57% to $1.1 billion in 2022, then climbed by 0.75% to $1.1 billion in 2023, then grew by 1.67% to $1.1 billion in 2024, then retreated by 7.32% to $1.0 billion in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $1.0 billion, $1.1 billion, and $1.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.00 Bn
Dec 31, 2024 1.08 Bn
Dec 31, 2023 1.06 Bn
Dec 31, 2022 1.06 Bn
Dec 31, 2021 725.26 Mn
Dec 31, 2020 663.88 Mn
Dec 31, 2019 377.23 Mn
Dec 31, 2018 333.13 Mn
Jun 30, 2018 470.02 Mn
Dec 31, 2017 457.92 Mn
Jun 30, 2017 629.10 Mn
Dec 31, 2016 648.53 Mn
Sep 30, 2016 676.26 Mn
Jun 30, 2016 702.52 Mn
Dec 31, 2015 692.27 Mn
Sep 30, 2015 654.33 Mn
Jun 30, 2015 628,910.48
Mar 31, 2015 673.10 Mn
Dec 31, 2014 673.39 Mn
Sep 30, 2014 704.28 Mn